NICOTINELL

Informació principal

  • Denominació comercial:
  • NICOTINELL 14 mg/24 h 7 parches transdérm 35 mg
  • Designació comuna internacional (DCI):
  • nicotine
  • formulario farmacéutico:
  • Parche
  • Vía de administración:
  • Transdérmica
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • NICOTINELL 14 mg/24 h 7 parches transdérm 35 mg
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 658197
  • última actualització:
  • 08-06-2018

Prospecte

NICOTINELL 14 mg/24 h 7 parches transd

rm

35 mg

nicotina

Indicacions

Medicament que s'utilitza per deixar de fumar (DESHABITUAMENT TAB

QUIC).

Consideracions

NO fumi en absolut mentre s'aplica aquest medicament.

Apliqui's el pegat sobre la pell seca, no irradiada, no irritada, sense ferides i sense borrissol (pot tallar el

borrissol amb tisores, per

no afaitar-lo).

Si ha d'aplicar un nou pegat, canvi

el lloc d'aplicaci

, per a qu

la pell no s'irriti.

Ha de guardar els pegats en un lloc sec, i evitar la calor i la llum solar directa.

Pot banyar-se, dutxar-se o practicar nataci

amb el pegat, per

eviti exposar-ho a una calor excessiva.

Segueixi estrictament la pauta indicada pel seu metge pel que fa a dosi i freq

眉猫

ncia d'administraci

Avisi el seu metge si pateix o ha patit problemes de cor o

lcera d'est

mac o de duod

Efectes adversos

Interrompi immediatament el tractament i AVISI al seu metge si durant el tractament apareix canvis en el

ritme del cor o mal al pit.

Aquest medicament pot produir insomni, agitaci

, irritabilitat, mal de cap, mareigs, mol

sties

gastrointestinals (n

usees, v

mits, etc.), mal de gola i augment de la quantitat de saliva.

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Ha de canviar el pegat cada dia, tot rotant el lloc d'aplicaci

VIA TRANSD

RMICA.

9-11-2018

First Choice Vapor recalls Unflavoured 100 mg Nicotine Base E-Liquids

First Choice Vapor recalls Unflavoured 100 mg Nicotine Base E-Liquids

These vaping products do not meet requirements of the Consumer Chemicals and Containers Regulations, 2001 (CCCR, 2001) under the Canada Consumer Product Safety Act.

Health Canada

3-8-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps the agency is taking to support the development of novel nicotine replacement drug therapies to help smokers quit cigarettes

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps the agency is taking to support the development of novel nicotine replacement drug therapies to help smokers quit cigarettes

FDA releases the first of two draft guidances aimed at supporting the development of novel, inhaled nicotine replacement therapies that could be submitted for approval as new drugs.

FDA - U.S. Food and Drug Administration

12-6-2018

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Teer, nicotine en koolmonoxide gehalten in sigaretten die gemeten worden volgens de Canadian Intense (CI) methode zijn minimaal twee keer zo hoog als de gehalten gemeten met de wettelijke voorgeschreven ISO methode waarmee de EU en dus ook Nederland werkt. In sommige gevallen liggen de gehaltes zelfs tot meer dan 20 keer hoger. Dat blijkt uit onderzoek van het RIVM, dat 100 sigaretten onder de loep nam. Staatssecretaris Paul Blokhuis (VWS) heeft als opdrachtgever het onderzoek vandaag in ontvangst genome...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

7-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on 2017 National Youth Tobacco Survey results and ongoing FDA efforts to protect youth from the dangers of nicotine and tobacco products

Statement from FDA Commissioner Scott Gottlieb, M.D., on 2017 National Youth Tobacco Survey results and ongoing FDA efforts to protect youth from the dangers of nicotine and tobacco products

Statement from FDA Commissioner Scott Gottlieb, M.D., on 2017 National Youth Tobacco Survey results and ongoing FDA efforts to protect youth from the dangers of nicotine and tobacco products

FDA - U.S. Food and Drug Administration

7-8-2018

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

FDA - U.S. Food and Drug Administration

16-7-2018

#FDA’s comprehensive plan that places nicotine and the issue of addiction at the center of our tobacco efforts. I’m optimistic about the opportunity to forge a new path for a heathier America. Learn more about the plan and how to submit public comments:

#FDA’s comprehensive plan that places nicotine and the issue of addiction at the center of our tobacco efforts. I’m optimistic about the opportunity to forge a new path for a heathier America. Learn more about the plan and how to submit public comments:

#FDA’s comprehensive plan that places nicotine and the issue of addiction at the center of our tobacco efforts. I’m optimistic about the opportunity to forge a new path for a heathier America. Learn more about the plan and how to submit public comments: https://go.usa.gov/xQ7Jb  pic.twitter.com/hQxiKdMZBK

FDA - U.S. Food and Drug Administration